EcoNetix, a climate-tech start-up based in Vienna, successfully raised a 7-digit seed investment round in March 2024. The round was led by Voltares Ventures, with participation from Persistent and asc impact.
MILAN, March 27, 2024 /PRNewswire/ — MTD (Medical Technology and Devices) has recently acquired Ypsomed’s pen needle and blood glucose monitoring (BGM) businesses, further strengthening its position as a global leader in the production of pen needles and expanding its diabetes care solution portfolio for both self-care and professional use worldwide.
MTD, the second largest manufacturer of pen needles globally, has announced the incorporation of Ypsomed’s pen needle and BGMs portfolio into its operations. Ypsomed, a leading developer and manufacturer of injection and infusion systems for self-medication, brings with it 40 years of experience. By combining the strong technologies and trademarks associated with Ypsomed’s pen needle business with MTD’s scale efficiencies, the partnership will ensure the long-term availability of a unique and innovative pen needle offering, manufactured exclusively in Europe.
„This acquisition will enable us to accelerate growth and enter new strategic markets, leveraging a broader product portfolio combining the 6-bevels and click technologies from Ypsomed and MTD’s thinnest and shortest 34G pen needle. We will integrate Ypsomed’s pen needles operations and BGMs’ commercialization into our European production and distribution sites, contributing to scale efficiencies and benefiting from our category expertise” – says Charles Bouaziz, CEO of MTD.
Charles Bouaziz, CEO of MTD, is excited about the partnership with Ypsomed and the opportunities it will provide. The acquisition of Ypsomed’s pen needle and blood glucose monitoring businesses will solidify MTD’s position as a global leader in pen needle production and enhance its comprehensive solution portfolio for diabetes care.
MTD, the second largest manufacturer of pen needles globally, will incorporate Ypsomed’s pen needle and BGMs portfolio into its operations. This will ensure the long-term availability of a unique and innovative pen needle offering, manufactured exclusively in Europe, leveraging MTD’s scale efficiencies.
As a result of this acquisition, MTD will be able to accelerate growth, enter new strategic markets, and strengthen its position in important markets. The closing of the transaction and transfer of the business is expected in summer 2024, subject to customary conditions.
„This acquisition – continues Bouaziz – enables MTD to open new, strategic markets, such as Germany, expand into high growth markets like China and India and strengthen our position in other important markets such as North America and France, reinforcing our commitment to supporting millions of diabetic patients, caregivers, and healthcare professionals worldwide”.
We anticipate the completion of the business transfer for pen needles and blood glucose monitoring systems in the summer of 2024. Following this, the transition process will commence, pending the fulfillment of standard conditions.
Medical Technology and Devices (MTD) is a global leader in the design, manufacturing, and distribution of medical devices for both professional and self-care use. With a history dating back to 2018, MTD was formed through the merger of Pikdare and HTL Strefa, bringing together extensive expertise in medical sharps, home-use electromedical devices, and pharma self-care products.
Operating in over 100 countries, MTD is committed to research and development, continuously striving to innovate and provide safe and effective healthcare products. With four state-of-the-art production plants in Europe and over 1,700 employees, MTD is dedicated to meeting the needs of healthcare professionals and individuals worldwide.
Źródło: pap-mediaroom.pl
